GTC Biotherapeutics Inc. of Framingham has been notified that the company no longer qualifies for trading on the Nasdaq Capital Market.
The notice is the result of GTC’s inability to meet the market’s $2.5 million stockholders’ equity requirement.
GTC said it plans to take advantage of the Nasdaq’s review, and if necessary, appeals processes. The company said it is “well positioned to regain compliance.”
GTC is developing an anti-clotting protein produced in the milk of genetically modified goats.
